Research Article
Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience
Table 3
Results of secondary endpoints at each visit.
| Endpoint (mean ± SD) | Visit 0 | Visit 1 | Visit 2 |
| TBUT (s) | 2.9 ± 1.3 | 3.6 ± 1.3 | 4.1 ± 1.3 | Change from V0 | N/A | 0.8 ± 1.5 | 1.2 ± 1.7 | -value | | <0.05 | <0.05 |
| Irritation/burning/stinging score | 0.7 ± 1.1 | 0.2 ± 0.4 | 0.3 ± 0.6 | Change from V0 | | −0.5 ± 1.1 | −0.4 ± 1.4 | -value | | N/A | N/A |
| Itching score | 0.2 ± 0.6 | 0.2 ± 0.6 | 0.2 ± 0.4 | Change from V0 | | −0.0 ± 0.7 | −0.1 ± 0.6 | -value | | N/A | N/A |
| Foreign body sensation score | 0.3 ± 0.8 | 0.2 ± 0.6 | 0.2 ± 0.4 | Change from V0 | | −0.1 ± 1.1 | −0.1 ± 0.9 | -value | | N/A | N/A |
| Tearing score | 0.3 ± 0.6 | 0.1 ± 0.5 | 0.2 ± 0.4 | Change from V0 | | −0.2 ± 0.8 | −0.1 ± 0.5 | -value | | N/A | N/A |
| Dry eye sensation score | 0.8 ± 0.8 | 0.4 ± 0.7 | 0.3 ± 0.5 | Change from V0 | | −0.5 ± 0.9 | −0.5 ± 0.8 | -value | | <0.05 | <0.05 |
|
|